GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma

Pallavi Madhiraju- November 28, 2023 0

GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple ... Read More

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Raghuram Kadari- December 28, 2022 0

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio ... Read More

Thermo Fisher to buy specialist protein diagnostics company Binding Site

Raghuram Kadari- November 1, 2022 0

Thermo Fisher Scientific has agreed to acquire The Binding Site Group, a UK-based specialist protein diagnostics company, for £2.25 billion ($2.6 billion) in an all-cash ... Read More

FDA approves Janssen’s TECVAYLI for multiple myeloma treatment

Pallavi Madhiraju- October 27, 2022 0

The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration's approval of its first bispecific T-cell engager antibody, ... Read More

Bristol Myers Squibb gets FDA priority review for Breyanzi sBLA

pallavi123- February 19, 2022 0

Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its supplemental biologics license application (sBLA) for Breyanzi ... Read More

Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD

pharmanewsdaily- June 18, 2020 0

Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for PTG-300 for polycythemia vera treatment. Polycythemia vera ... Read More

Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma

pharmanewsdaily- October 30, 2019 0

Cellectis said that it has dosed the first patient in a phase 1  study - the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf ... Read More

Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial

pharmanewsdaily- February 26, 2017 0

Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More

Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia

pharmanewsdaily- February 23, 2017 0

Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its innovative blood cancer drug, inotuzumab ozogamicin. This ... Read More